ReviewCurrent psychiatry reports2016
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.
Review in Current psychiatry reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.Journal of affective disorders · 2022Trial
- The prospect of suicide biomarkers: from neurobiology to precision prevention.Frontiers in psychology · 2026Review
- Heightened effective connectivity of DLPFC-mPFC and DLPFC-ACC circuits in major depressive disorder with suicidal ideation: evidence from a TMS-EEG study.Translational psychiatry · 2025Article
- A feasibility study of low-dose ketamine for acute management of suicidal ideation.Journal of the American College of Emergency Physicians open · 2022Article
- A Review of Nonanesthetic Uses of Ketamine.Anesthesiology research and practice · 2020Review
- Infusing hope into the treatment of suicidality: A review of ketamine's effects on suicidality.Current behavioral neuroscience reports · 2019Article
- NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity.Molecular psychiatry · 2019Article
- Subanesthetic Dose Ketamine in Posttraumatic Stress Disorder: A Role for Reconsolidation During Trauma-Focused Psychotherapy?Current topics in behavioral neurosciencesArticle
- (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy.Chronic stress (Thousand Oaks, Calif.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketamine, an NMDA receptor antagonist with efficacy as a rapid anti-depressant, has early evidence for action to reduce suicidal ideation. This review will explore several important questions that arise from these studies. First, how do we measure reductions in suicidal ideation that occur over minutes to hours? Second, are the reductions in suicidal ideation after ketamine treatment solely a result of its rapid anti-depressant effect? Third, is ketamine only effective in reducing suicidal ideation in patients with mood disorders? Fourth, could ketamine's action lead us to a greater understanding of the neurobiology of suicidal processes? Last, do the reductions in depression and suicidal ideation after ketamine treatment translate into decreased risk for suicidal behavior? Our review concludes that ketamine treatment can be seen as a double-edged sword, clinically to help provide treatment for acutely suicidal patients and experimentally to explore the neurobiological nature of suicidal ideation and suicidal behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.